Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Vertex

    - PMLiVE

    BMS acquires Orbital Therapeutics in $1.5bn deal

    The deal includes several next-gen cell therapy candidates for autoimmune diseases

    - PMLiVE

    Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

    The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

    - PMLiVE

    AstraZeneca announces $3.5bn US investment to boost research and manufacturing

    The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

    - PMLiVE

    Study finds siblings with unique genetic defects could help progress type 1 diabetes drug search

    The chronic, life-long disease affected around 8.4 million people worldwide in 2021

    - PMLiVE

    NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

    Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

    - PMLiVE

    Two KCL research projects awarded £4.8m to help find cure for type 1 diabetes

    The Type 1 Diabetes Grand Challenge has awarded six research projects grants totalling £13m

    - PMLiVE

    Kite and Arcellx expand cell therapy partnership in deal worth over $285m

    The companies' existing CART-ddBCMA collaboration now covers lymphomas

    - PMLiVE

    Kite and Epic Bio announce cancer cell therapy collaboration agreement

    The partnership centres around Epic Bio’s proprietary gene regulation platform

    - PMLiVE

    Novo Nordisk Foundation commits €127m for new cell therapy facility

    The new facility will help accelerate treatments for people living with chronic diseases

    - PMLiVE

    Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

    The company will gain the first refusal to one of Poseida’s clinical stage programmes

    - PMLiVE

    New study shows AI model can identify where patients’ cancers originated

    The predictions from OncoNPC could enable doctors to choose targeted cancer treatments

    - PMLiVE

    Eli Lilly to acquire Sigilon in deal worth over $300m

    The companies have been working together since 2018 on cell therapies for type 1 diabetes

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links